Beijing Hotgen Biotech (SHA:688068) recently obtained 35 overseas qualification certifications, according to a Tuesday filing with the Shanghai bourse.
These certifications cover a range of diagnostic reagents and equipment as well as biochemical tests mainly in the European Union, Indonesia and Cambodia.
Shares of the in vitro diagnostic device manufacturer closed 3% lower Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。